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 Diabetes is a public health problem in Indonesia that has been increasing in 
recent decades. Screening for diabetes was usually identified as pregnant 
women, adolescents, adults, children, older and obesity, while based on 
investigation descendent was yet. This cross-sectional study aimed to know 
the random level blood glucose of family history type 2 diabetes mellitus 
(T2DM). The target group for screening was people with a family history in 
one of their descent of T2DM with age >20 years in Kulon Progo, DIY, 
Indonesia. We conducted a detection of random level blood glucose from a 
venous blood sample. A high level of blood glucose was diagnosed when 
random blood glucose reaches ≥200 mg/dl. The participant with high level of 
blood glucose was 29.0%, while borderline blood glucose (≥110-199 mg/dl) 
was revealed 38.7% of 15.3% subject indicated with mother history. 
Descendant screening of family history T2DM is early detected respondent 
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1. INTRODUCTION  
Type 2 Diabetes Mellitus (T2DM) is one of the chronic disease problems fourth in Indonesia.  
The estimated prevalence of diabetes among adults in the Indonesia population is now 7.0% in 2017 [1].  
Based on reported diabetes, the higher country is India in Asia [1, 2]. Diabetes one of the risk factors present 
in an individual; the higher the chance of that individual having diabetes without symptoms.  
Many people descendants of diabetes undiagnosed of T2DM. Ideally, screening before the patient reports 
symptoms [2-6]. 
Without screening, more any risk with risk undiagnosed T2DM [7] Screening for descendants of 
patient T2DM is not widely undertaken due to the high costs and did not have care health [8]. Screening is an 
asymptomatic test to classify a person for their likelihood of having a particular disease [7]. Screening would 
be more useful and efficient when directed at target populations at high risk [5, 9]. Besides, a high-risk 
population is generally more motivated to participate in screening programs and tend to follow up on  
the action if the recommendations positive results [9]. Screening descendants of T2DM are useful for  
the prevention of complications and early detection [5, 6, 10].  
Recommended screening for type 2 diabetes because it is chronic, and patients often do not realize 
that the complaints that arise are clinical symptoms, so they are newly diagnosed diabetes if it appeared 
complications [7, 11]. Most patients with T2DM had complications (e.g., cardiovascular, kidney disease, 
etc.), and its complication is the leading cause of morbidity and mortality in these patients [12-14].  
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Screening diabetes mellitus is the primary of successful diabetes management for helping these patients to 
modify and reducing the risk factors of this complication [15]. As our best our knowledge, to date, many 
previous studies considering diabetes screening, no reporting screening among descendants of family 
diabetes, especially in Indonesia. This study was undertaken to screening the number of people in having risk 
high glucose descendants of T2DM. This approach has the advantage that the existence of early detection, 
prevent complication and intervention treatment for a high glucose level. 
 
 
2. RESEARCH METHOD  
2.1.  Study setting and population 
A cross-sectional study was done in June 2015 year. The population was a type 2 diabetic patients 
who went to the Panjatan II Public Health Center. The subjects were descendants of patients with type 2 
diabetes, men and women, aged >20 years, issues have not been diagnosed by a health worker and willing to 
be a respondent. The determine sample size based error rate of 10% [16, 17], the prevalence of Panjatan II 
health center was 0.25%. The sample size was 62 respondents-locations of screening in Kulon progo District. 
 
2.2 Data collection and analysis 
In this study, income data were random blood glucose from venous blood. Method enzymatic used 
to auto analyzer Cobas C 111 as the gold standard. High glucose level was defined as having random blood 
glucose (RBG) reaches ≥200 mg/dl [1, 5, 18, 19]. We described the respondent’s characteristics with 
percentages. We set high-risk factor TD2M is a high glucose level, and we identified who had a family 
history with T2DM (ex: mother, father, or both).  Individuals with high glucose levels/hyperglycemic are 
significantly higher risk factor T2DM than glucose average [20, 21]. Early detection and prompt treatment 
method were recommended by WHO to reduce the burden of diabetes and complications [5, 22].  




3. RESULTS AND DISCUSSION 
The result of this study showed that identifying people at high-risk factor T2DM (family history).  
A total of 62 respondents met the inclusion criteria for this study, which are 27 males and 35 females.  
Most of the respondents are in 31-40 years old and in borderline high of blood glucose level and have a factor 
of T2DM from mother. In our study, of high glucose level (30.6%), the rate of random blood glucose 
performers increased with age ≥40 years a had greater as shown in Table 1. Screening descendants of T2DM 
(family history) consist of 26 heads of families showed that the households (34.4%) with random blood sugar 
levels ≥200 mg/dL as shown in Table 2 include of T2DM family history of a father, mother or both as shown 
in Table 3. 
 
 
Table 1. Baseline characteristics of sex, and age group (n=62) 




a. Age Groups  
20-30 years 14.52 
31-40 years 33.87 
41-50 years 29.03 
≥ 51 years 22.58 
 
 
Table 2. Random blood glucose level with autoanalyzer tests 
A result from random blood glucose Test Result test (%) 
Desirable (<110 mg/dl) 30.6 
Borderline high (≥110-199 mg/dl) 38.7 
High (≥200 mg/dl) 30.7 
Data are presented as percentages (%). 
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In our study, of high glucose level (30.6%), the rate of random blood glucose performers increased 
with age ≥40 years a had greater as shown in Table 3. Screening descendants of T2DM (family history) 
consist of 26 heads of families showed that the households (34.4%) with random blood sugar levels ≥200 
mg/dL as shown in Table 2 include of T2DM family history of a father, mother or both. Screening should be 
more productive and efficient when directed at target populations at high risk. In addition, a high-risk 
population is generally more motivated to participate in screening programs and tend to follow the action if 
the recommendations positive results [4, 23].  
 
 
Table 3. Distribution of the sample according to sex, and age 
Characteristics 
Blood random glucose  ≥ 200 mg/dL 
Value (n) % 
Sex 
  
Women 10 16.1 
Men 9 14.5 
Age Groups 
  20-30 years 0 0 
31-40 years 5 8.0 
≥41 years 14 22.5 
Family History   
Father 1 3.8 
Mother 4 15.3 
Father and Mother 4 15.3 
 
 
Several studies have been screening in various populations. The majority of previous research found 
that respondents recruited were not descendants of T2DM patients [7, 20, 24, 25], blood sugar levels were 
more often in pregnant women [1, 23, 26-28], children [29], HbA1c compared with oral glucose tolerance for 
T2DM patients and pre-diabetes [11], HbA1c for screening and diagnosis of diabetes mellitus [30].  
This research was conducted in the population, and the sample size was more focused and specific.  
To the best of our knowledge, screening descendants of T2DM are widely yet done in a population-based on 
sample family history of T2DM patients. Therefore, the aim of this survey is expected to be able to detect 
early and prevent people with high-risk factor T2DM and complications. Our research has a few limitations 
that need to be discussed. The first is the level of low awareness concerning early detection, and health self 
so that in seeking participation requires more effort. The second mostly unexplored in population-based 
samples in Asian countries, such as Indonesia and no funder received. This study different from other 
research participation in early detection screening of T2DM [7, 1, 9, 19, 24, 28], this research screening 
followed of descendants (family history) T2DM. We documented the enzymatic test. This research also 
shows must be follow-up screening enables having a high risk of T2DM. Our study furthermore demonstrates 
the enormous potential of monitoring treatment having a high glucose level. 
 
 
4. CONCLUSION  
In this research screening descendant of type 2 diabetes mellitus in Kulonprogo district,  
we found 19 cases (29%) high random blood glucose level reaches ≥200 mg/dl and only 15.3% subjects 
indicated with mother history of this disease. This study has documented the need for preventive health  
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